DOCSLIB.ORG

• Vaccines Guidance Document 16 June 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

• Vaccines Guidance document 16 June 2021 Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process Manufacturer / Name of Vaccine NRA of Record Platform EOI Pre-submission Dossier accepted Status of Decision WHO EUL holder accepted meeting held for review* assessment** date*** 1. BNT162b2/COMIRNATY EMA Nucleoside modified Finalized 31/12/20 Tozinameran (INN) mNRA 2. AZD1222 EMA Recombinant ChAdOx1 Core data finalized 16 April 2021 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. Data for Covax Finalized: SK-Catalent 16 April 2021 sites expected in Wuxi (DS) 30 April 2021 April 2021 Chemo Spain 04 June 2021 onwards Other sites As submitted 3. AZD1222 MFDS KOREA Recombinant ChAdOx1 Finalized 15 Feb 2021 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. 4. Covishield DCGI Recombinant ChAdOx1 Finalized 15 Feb 2021 (ChAdOx1_nCoV-19) adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2. 5. Ad26.COV2.S EMA Recombinant, replication- Core data finalized (US 12 March 2021 incompetent adenovirus +NL sites) type 26 (Ad26) vectored vaccine encoding the Additional sites: (SARS-CoV-2) Spike (S) - Aspen South - Ongoing* - June 2021 protein Africa - Awaited - As submitted - Other sites 6. mRNA-1273 EMA mNRA-based vaccine Finalized 30 April 2021 encapsulated in lipid nanoparticle (LNP) 7. 1 SARS-CoV-2 Vaccine NMPA Inactivated, produced in Finalized 07 May 2021 Sinopharm / BIBP (Vero Cell), Inactivated Vero cells (lnCoV) Page 1 • Vaccines Guidance document 16 June 2021 Manufacturer / Name of Vaccine NRA of Record Platform EOI Pre-submission Dossier accepted Status of Decision WHO EUL holder accepted meeting held for review* assessment** date*** 8. SARS-CoV-2 Vaccine NMPA Inactivated, produced in Finalized 01 June 2021 (Vero Cell), Inactivated Vero cells 9. Sputnik V Russian NRA Human Adenovirus Vector- Additional Several meetings “Rolling” Additional data (Non- Anticipated based Covid-19 vaccine information have been and submission of CLIN, CLIN, CMC) date will be set submitted continue to be clinical and CMC Required. once all data is held. data has started. Following up on submitted and inspection follow-up of observations. inspection observations completed. 10. AZD1222 Japan Recombinant ChAdOx1 Submission from AZ Several meetings Ongoing Anticipated MHLW/PMDA adenoviral vector encoding received on 15 June held separately date will be set the Spike protein antigen with AZ and once all of the SARS-CoV-2. MHLW submiited MHLW/PMDA information has review and GMP been received reports on 16 June 2021. More expected on June 22. 11. AZD1222 Australia TGA Recombinant ChAdOx1 Submission from AZ Several meetings Ongoing Anticipated adenoviral vector encoding received on 11 June held separately date will be set the Spike protein antigen with AZ and TGA once all of the SARS-CoV-2. information has been received 12. Ad5-nCoV NMPA Recombinant Novel Rolling data Coronavirus Vaccine starting June (Adenovirus Type 5 Vector) 2021 13. NVX-CoV2373/Covovax EMA Recombinant nanoparticle prefusion spike protein formulated with Matrix- M™ adjuvant. 14. 2 Inactivated SARS-CoV-2 NMPA Inactivated, produced in Sinopharm / WIBP Vaccine (Vero Cell) Vero cells Page 2 • Vaccines Guidance document 16 June 2021 Manufacturer / Name of Vaccine NRA of Record Platform EOI Pre-submission Dossier accepted Status of Decision WHO EUL holder accepted meeting held for review* assessment** date*** 15. Zorecimeran (INN) EMA mNRA-based vaccine Planned for 15 concentrate and encapsulated in lipid July 2021, solvent for dispersion nanoparticle (LNP) for injection; Company code: CVnCoV/CV07050101 16. Bharat Biotech, India COVAXIN DCGI SARS-CoV-2 Vaccine, Planned for 23 Inactivated (Vero Cell) June 2021 17. Sanofi Pasteur CoV2 preS dTM-AS03 EMA Recombinant, adjuvanted Planning in vaccine process 18. Vector State Research EpiVacCorona Russian NRA Peptide antigen Letter received not Centre of Viralogy and EOI. Reply sent on Biotechnology 15/01/2021 19. Zhifei Longcom, China Recombinant Novel NMPA Recombinant protein Response to 2nd EOI Coronavirus Vaccine subunit sent 29 Jan 2021. （CHO Cell) Additional information requested. 20. IMBCAMS, China SARS-CoV-2 Vaccine, NMPA Inactivated Not accepted, still Inactivated (Vero Cell) under initial development 21. Clover Biopharmaceuticals SCB-2019 EMA Novel recombinant SARS- In discussion on CoV-2 Spike (S)-Trimer submission strategy fusion protein and timelines 22. BioCubaFarma - Cuba Soberana 01, CECMED SARS-CoV-2 spike protein Awaiting information Soberana 02 conjugated chemically to on strategy and Soberana Plus meningococcal B or timelines for Abdala tetanus toxoid or submission. Aluminum 1. Beijing Institute of Biological Products Co-Ltd * Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission. 2. Wuhan Institute of Biological Products Co Ltd **Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made *** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors’ questions are submitted. Page 3.
Recommended publications
  • Considerations for Causality Assessment of Neurological And

    Considerations for Causality Assessment of Neurological And

    Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors.
  • National Emergency Management Organisation (Nemo) Ministry of National Security St

    National Emergency Management Organisation (Nemo) Ministry of National Security St

    NATIONAL EMERGENCY MANAGEMENT ORGANISATION (NEMO) MINISTRY OF NATIONAL SECURITY ST. VINCENT AND THE GRENADINES WEST INDIES Tel: 784-456-2975, Fax: 784-457-1691, Email: [email protected] or [email protected] ______________________________________________________________________________ ___________________________________________________________________________________________________________________ HEALTH SERVICES SUBCOMMITTEE PROTOCOL FOR THE ENTRY OF FULLY VACCINATED TRAVELLERS TO ST. VINCENT AND THE GRENADINES – revised 10/08/2021 AIM: The safe entry of travellers to St. Vincent and the Grenadines in a manner that reduces the risk of the importation and subsequent transmission of COVID-19 in St. Vincent and the Grenadines. OBJECTIVES: 1. To establish the risk of the arriving traveller introducing new COVID-19 cases to SVG; 2. To minimize exposure of residents of SVG to new COVID-19 cases; 3. Early identification of potential exposure to COVID-19 and 4. Early containment of new COVID-19 cases. ESTABLISH RISK OF ARRIVING TRAVELLER: The arriving traveller will: 1. Complete the Pre-Arrival Form available at health.gov.vc And the Port Health Officer will: 1. Review Port Health form for each arriving passenger. 1 PHASED PROCESS OF ENTRY OF FULLY VACCINATED TRAVELERS TO ST. VINCENT AND THE GRENADINES: TESTING & QUARANTINE: PHASE #16 - Commencing Wednesday, August 11, 2021: 1. Where ‘Fully Vaccinated Travelers’ are those persons who: a. Have completed a vaccination regimen with one of the following COVID-19 vaccines recognized by the Ministry of Health, Wellness and the Environment of St Vincent and the Grenadines: i. AstraZeneca – Oxford AstraZeneca (Vaxzevria), COVISHIELD, AstraZeneca COVID-19 vaccine by SK Bioscience; ii. Pfizer-BioNTech COVID-19 vaccine; iii. Moderna COVID-19 vaccine; iv.
  • WHO COVID-19 Database Search Strategy (Updated 26 May 2021)

    WHO COVID-19 Database Search Strategy (Updated 26 May 2021)

    Search purpose: Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Use following commands to pull daily new entries: Entry_date:( [20210101 TO 20210120]) Entry_date:( 20210105) Duplicates: Duplicates are found in EndNote and Distillr using the Wichor method. Further screening is done by expert reviewers but some duplicates may still be in the database. Daily Search Strategy: Database Daily Search Strategy Medline (coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR (Ovid) nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus* OR 1946- NCOV19 OR solidarity trial OR operation warp speed OR COVAX OR "ACT-Accelerator" OR BNT162b2 OR comirnaty OR "mRNA-1273" OR CoviShield OR AZD1222 OR Sputnik V OR CoronaVac OR "BBIBP-CorV" OR "Ad26.CoV2.S" OR "JNJ-78436735" OR Ad26COVS1 OR VAC31518 OR EpiVacCorona OR Convidicea OR "Ad5-nCoV" OR Covaxin OR CoviVac OR ZF2001 OR "NVX-CoV2373" OR "ZyCoV-D" OR CIGB 66 OR CVnCoV OR "INO-4800" OR "VIR-7831" OR "UB-612" OR BNT162 OR Soberana 1 OR Soberana 2 OR "B.1.1.7" OR "VOC 202012/01" OR "VOC202012/01" OR "VUI 202012/01" OR "VUI202012/01" OR "501Y.V1" OR UK Variant OR Kent Variant OR "VOC 202102/02" OR "VOC202102/02" OR "B.1.351" OR "VOC 202012/02" OR "VOC202012/02" OR "20H/501.V2" OR "20H/501Y.V2" OR "501Y.V2" OR "501.V2" OR South African Variant OR "B.1.1.28.1" OR "B.1.1.28" OR "B.1.1.248" OR
  • Periodic Update on AEFI

    Periodic Update on AEFI

    CONSOLIDATED REGIONAL AND GLOBAL INFORMATION ON ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI) AGAINST COVID-19 AND OTHER UPDATES WASHINGTON, DC Updated: 31 March 2021 1 OFFICIAL REPORTS ON PHARMACOVIGILANCE PROGRAMS CANADA § As of 19 March 2021, 3,729,312 doses of the Pfizer-BioNTech, Moderna, and Covishield vaccines had been administered. § A total of 2,530 individual reports of one or more adverse events (0.068% of doses administered) were reported. Of these, 320 were considered serious events (0.009% of doses administered), with anaphylaxis being the most frequently reported. § There were a total of 7,397 adverse events following immunization (AEFI) (consisting of 2,530 reports of one or more events), mostly non-serious adverse events, such as injection-site reactions, partesia, itching, hives, headache, hyposthesia, and nausea. Only 0.8% of cases corresponded to anaphylaxis (59 cases, or 15.8 cases per million doses administered). § Most adverse events reported were among women, and in people between the ages of 18 and 49, these being the groups prioritized for vaccination § A total of 24 reported adverse events were identified as post-vaccination deaths. After medical review, it was determined that 13 of these deaths were not linked to administration of the COVID-19 vaccine, while the other 11 are still under investigation. Link: https://health-infobase.canada.ca/covid-19/vaccine-safety/ UNITED STATES § Nearly 126 million doses of the Pfizer-BioNTech and Moderna vaccines were administered between 14 December 2020 and 29 March 2021. § The Vaccine Adverse Event Reporting System (VAERS) received 2,509 reports of deaths (0.0019% of doses administered) that have not been linked to the vaccine.
  • Summit of G20 Argentina

    Summit of G20 Argentina

    Boletín informativo del Ministerio de Relaciones Exteriores, Comercio Internacional y Culto de la República Argentina 1 July 20, 2021 SUMMIT OF G20 Solá: “We have the opportunity to create a better economy with less inequality” ARGENTINA - UNITED STATES Bilateral Meeting of Foreign Minister Solá and Secretary of State Antony Blinken Solá at G20 Summit: “We have the opportunity to create a better economy with less inequality” 2 “Today, more than ever, we must strengthen organizations at Palazzo Lanfranchi, the Minister international cooperation and solidarity to achieve highlighted the importance of “preparedness for inclusive and sustainable post-COVID-19 recovery,” and response to health emergencies, based on Foreign Minister Felipe Solá stated during the G20 international solidarity and cooperation” in order to Foreign Affairs and Development Ministerial “prevent future epidemics from becoming new Meeting, held on 29 June in Matera, Italy, one of the global catastrophes.” objectives of which was to discuss ways to strengthen “multilateralism and global governance” “We need a common global growth plan that allows in view of the urgent problems facing the for coordinated fiscal and monetary interventions in international community. order to avoid unequal and unbalanced recovery and that guarantees a more equal future,” Solá Solá referred to the serious social and economic stated during his first address, adding that “we have effects of the pandemic, and advocated “redoubling the opportunity to create a better economy that efforts to guarantee global mass vaccination and produces less carbon, creates less inequality, and promote voluntary licensing agreements that provides digital access and access to new enable the necessary transfer of knowledge and technologies for all.
  • The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia's Vaccine

    The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia's Vaccine

    Article The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia’s Vaccine Rollout Slower than That of Other Nations? Elza Mikule 1,*,† , Tuuli Reissaar 1,† , Jennifer Villers 1,† , Alain Simplice Takoupo Penka 1,† , Alexander Temerev 2 and Liudmila Rozanova 2 1 Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland; [email protected] (T.R.); [email protected] (J.V.); [email protected] (A.S.T.P.) 2 Institute of Global Health, University of Geneva, 1202 Geneva, Switzerland; [email protected] (A.T.); [email protected] (L.R.) * Correspondence: [email protected] † These authors contributed equally. Abstract: The emergence of the SARS-CoV-2 pandemic in the beginning of 2020 led to the deployment of enormous amounts of resources by different countries for vaccine development, and the Russian Federation was the first country in the world to approve a COVID-19 vaccine on 11 August 2020. In our research we sought to crystallize why the rollout of Sputnik V has been relatively slow considering that it was the first COVID-19 vaccine approved in the world. We looked at production capacity, at the number of vaccine doses domestically administered and internationally exported, and at vaccine hesitancy levels. By 6 May 2021, more first doses of Sputnik V had been administered Citation: Mikule, E.; Reissaar, T.; abroad than domestically, suggesting that limited production capacity was unlikely to be the main Villers, J.; Takoupo Penka, A.S.; reason behind the slow rollout. What remains unclear, however, is why Russia prioritized vaccine Temerev, A.; Rozanova, L.
  • Abdala COVID-19 Vaccine Candidate Begins Phase II of Trials

    Abdala COVID-19 Vaccine Candidate Begins Phase II of Trials

    Abdala COVID-19 vaccine candidate begins phase II of trials Doctor in Sciences Marta Ayala Avila, director of the Center for Genetic Engineering and Biotechnology (CIGB) Havana, February 2 (RHC)-- Phase II of the clinical trial of the Abdala vaccine candidate (CIGB 66) against COVID-19 has begun at the Saturnino Lora Hospital in the eastern city of Santiago de Cuba. This phase will be performed with 760 volunteers. Doctor in Sciences Marta Ayala Avila, member of the Political Bureau and general director of the Center for Genetic Engineering and Biotechnology (CIGB), informed that while in phase I participants were aged between 19 and 54 years,in the new stage, the range is extended up to 80. "Only the intramuscular mode of administration is explored, with the study of two dose levels of 25 and 50 micrograms, with three administrations of the corresponding doses and different time intervals in between. Also, a placebo group was included," specified Ayala Avila. The Center for Genetic Engineering and Biotechnology is working simultaneously with the candidate Mambisa (CIGB 669). Both potential COVID-19 vaccines began their trials on December 7 last year and 56 days after administration have proven safe, with minimal adverse effects, such as mild pain in the vaccination area. Abdala and Mambisa, together with the Soberana series of the Finlay Vaccine Institute, show Cuba's scientific strength and the hope that the island's population can be immunized against the deadly SARS- COV-2. https://www.radiohc.cu/en/noticias/nacionales/246457-abdala-covid-19-vaccine-candidate-begins-phase-ii- of-trials Radio Habana Cuba.
  • Building Visualizations to Uncover Insights in Clinical Trial and Pipeline Data

    Building Visualizations to Uncover Insights in Clinical Trial and Pipeline Data

    Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Matt Eberle, Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. Diane Webb, President and Co-Founder, BizInt Solutions, Inc. Wednesday, March 24, 2021, 2:00 pm ET This session will start momentarily…. Webinar Host Susie Corbett PHT Chair Pharmaceutical & Health Technology Community https://connect.sla.org/pht/home Matt Eberle Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. [email protected] Following over ten years of experience at Wyeth, Pfizer and Sunovion as a Senior Information Scientist and Pharmaceutical Information Analyst, since 2013 Matt has helped BizInt customers use the BizInt Smart Charts and VantagePoint tools to create new solutions to address their challenges and problems. Matt lives outside Boston, MA. Diane Webb President and Co-Founder, BizInt Solutions, Inc. [email protected] Diane has over 30 years of experience managing the development of software tools to analyze and present competitive intelligence information, with a focus on drug pipeline, clinical trial and patent data. In 1996 Diane and John Willmore started BizInt Solutions to develop and market the BizInt Smart Charts product family. Diane & John live near Seattle, WA, with their current pack of four longhaired dachshunds. Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Part I: Dashboard visualizations and initial challenges PHT Pharma
  • SARS-Cov-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?

    SARS-Cov-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?

    PERSPECTIVES www.jasn.org SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know? Madeleine R. Heldman and Ajit P. Limaye Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington JASN 32: ccc–ccc, 2021. doi: https://doi.org/10.1681/ASN.2021010023 Coronavirus disease 2019 (COVID-19) will far outweigh risks of vaccination. viral vector–based vaccines could be- has had a major effect on kidney and Accordingly, current guidance from come replication competent and cause other solid organ transplant recipients.1 multiple professional organizations disease, especially in immunocompro- In addition to public health measures, recommend vaccination for all eligible mised individuals. For example, in cells improved access to testing, and thera- organ transplant recipients.2,4,5 concurrently infected with two different peutic developments, vaccination has Each vaccine platform has distinct AdVes, homologous recombination of emerged as a key tool for controlling safety considerations for kidney transplant genetic elements could occur and result the ongoing pandemic. In December recipients. Live (replication-competent) in the emergence of new, pathogenic, 2020, multiple regulatory agencies vaccines are generally contraindicated in replication-competent AdV types.9 This worldwide authorized the use of two immunocompromised individuals be- has been observed in patients with ad- mRNAvaccines for severe acute respiratory cause of a risk of vaccine-acquired
  • Download Preprint

    Download Preprint

    1 Title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 2 SARS-CoV-2 and variants of concern 3 4 Authors: Thibault Fiolet1*, Yousra Kherabi2,3, Conor-James MacDonald1, Jade Ghosn2,3, Nathan 5 Peiffer-Smadja2,3,4 6 7 1Paris-Saclay University, UVSQ, INSERM, Gustave Roussy, "Exposome and Heredity" team, CESP 8 UMR1018, Villejuif, France 9 2Université de Paris, IAME, INSERM, Paris, France 10 11 3Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, AP-HP, Paris, France 12 13 4National Institute for Health Research Health Protection Research Unit in Healthcare Associated 14 Infections and Antimicrobial Resistance, Imperial College, London, UK 15 16 *Corresponding author: 17 Email: [email protected] 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 1 48 Abstract 49 Vaccines are critical cost-effective tools to control the COVID-19 pandemic. However, the emergence 50 of more transmissible SARS-CoV-2 variants may threaten the potential herd immunity sought from 51 mass vaccination campaigns. 52 The objective of this study was to provide an up-to-date comparative analysis of the characteristics, 53 adverse events, efficacy, effectiveness and impact of the variants of concern (Alpha, Beta, Gamma and 54 Delta) for fourteen currently authorized COVID-19 vaccines (BNT16b2, mRNA-1273, AZD1222, 55 Ad26.COV2.S, Sputnik V, NVX-CoV2373, Ad5-nCoV, CoronaVac, BBIBP-CorV, COVAXIN, 56 Wuhan Sinopharm vaccine, QazCovid-In, Abdala and ZF200) and two vaccines (CVnCoV and NVX- 57 CoV2373) currently in rolling review in several national drug agencies.
  • Evolution of the COVID-19 Vaccine Development Landscape

    Evolution of the COVID-19 Vaccine Development Landscape

    https://doi.org/10.1038/d41573-020-00151-8 Supplementary information Evolution of the COVID-19 vaccine development landscape In the format provided by the authors Nature Reviews Drug Discovery | www.nature.com/nrd Supplementary Table 1 | COVID-19 vaccines in clinical development* Candidate Lead partners Vaccine characteristics Start of first Current stage Location (current phase I trial and upcoming trials) Viral vector (including replicating and non-replicating) Ad5-nCoV CanSino Biological/ Adenovirus type 5 vector that 17 Mar 20 Phase II CHN, CAN, UAE, PAK, Beijing Institute of expresses S protein (ChiCTR2000031781) MEX, BRZ, RUS Biotechnology Approved for military use in China LV-SMENP-DC Shenzhen GIMI DCs modified with lentiviral 24 Mar 20 Phase I/II CHN vector expressing synthetic (NCT04276896) minigene based on domains of selected viral proteins AZD1222 AstraZeneca/ ChAdOx1 vector that expresses 23 Apr 20 Phase III BRZ, GBR, ZAF, USA, Oxford University S protein (NCT04516746) IND, BGD Gam-COVID-Vac Gamaleya Research Recombinant adenovirus vector 18 Jun 20 Phase III RUS, KAZ, BLR, BRZ, Institute based on the human adenovirus (NCT04530396) MEX type 5, 26, containing S protein Conditional registration in Russia Ad26.COV2-S J&J – Janssen Adenovirus type 26 vector that 22 Jul 20 Phase I/II USA, BEL, BRZ, CHL, expresses S protein (NCT04436276) COL, MEX, PER, PHL, ZAF, UKR, ARG Pathogen-specific Shenzhen GIMI aAPCs modified with lentiviral Feb 20 Phase I CHN aAPC vector expressing synthetic (NCT04299724) minigene based on domains of selected
  • The Covid–19 Pandemic and Haemglobin Isorders

    The Covid–19 Pandemic and Haemglobin Isorders

    THE COVID–19 PANDEMIC AND HAEMGLOBIN ISORDERS UPDATE: 29 June 2021 Vaccinations “Immunization is a key component of primary health care and an indisputable human right. It is also one of the best health investments money can buy. Vaccines are thus critical to the prevention and control of infectious-disease outbreaks. They underpin global health security and will be a vital tool in the battle against antimicrobial resistance”. – WHO https://www.who.int/health- topics/vaccines-and- immunization “Since the beginning of the pandemic, WHO has taken steps to prevent an “infodemic”— defined by the organization as “an overabundance of information and the rapid spread of misleading or fabricated news, images, and videos.” WHO and the Wikimedia Foundation, the nonprofit organization that administers Wikipedia, have established a collaboration to expand the public’s access to the latest and most reliable information about COVID-19”. Information about the initiative is available at: https://www.who.int/news/item/22-10- 2020- the-world-health-organization-and-wikimedia-foundation-expand-access-to- trusted- information-aboutcovid-19-on-wikipedia TIF shares the concerns of false information and misleading overabundance of information. This often happens in the effort to enhance hope to a population that is suffering not only from the disease itself, but also from its economic future, since lockdown/isolation practices are stifling the market economies of every country around the world. Hope however, must be based on realistic expectations and information. For these reasons, TIF updates on new developments concerning vaccinations and new therapies are scanned for accuracy and are reviewed now more regularly.